Ramantamig Achieves “Impressive” Rates of MRD Negativity in RRMM

In the phase 1 TRIlogy-1 trial (NCT05652335), the trispecific antibody ramantamig (JNJ-5322) produced minimal residual disease (MRD) negativity in 95% of evaluable patients at the 10⁻⁵ threshold and 93.3% at the deeper 10⁻⁶ threshold.These results were achieved with monotherapy in patients with triple-class exposed relapsed/refractory multiple myeloma who had a median of 3 prior lines of therapy and were nearly all refractory to anti-CD38 agents.

Jeffrey V. Matous, MD, a member physician at the Colorado Blood Cancer Institute at Presbyterian St. Luke’s Medical Center, part of the Sarah Cannon Blood Cancer Network, and a clinical professor of Medicine at the University of Colorado Health Sciences Center, presented these findings at the 23rd Annual International Myeloma Society (IMS) Meeting & Exposition. He spoke with CancerNetwork® about how clinicians should interpret these MRD data and whether MRD negativity is becoming a standard benchmark for bispecific and trispecific antibody trials.

Transcript:

CancerNetwork: How should clinicians interpret the MRD negativity data of ramantamig in this setting? Do you see MRD negativity becoming a more standard benchmark for bispecific/trispecific trials going forward?

Matous: In this trial, we did assess measurable residual disease, or MRD, status in the patients; not all 56 patients had undergone MRD testing, but for those who had, we had very high rates of MRD negativity; 95% at the 10⁻⁵ threshold, and 93% at the 10⁻⁶ threshold. Why is this important? I think all of us in the myeloma world know that achievement of MRD negativity is increasingly recognized as an important end point, not just for clinical trials, but for prognosis for our patients. It’s the goal of many of our therapies in myeloma to achieve, or even sustain, MRD negativity.

To achieve these rates with a monotherapy in the relapsed/refractory setting, in a group of patients who had a median of 3 prior lines of therapy and were essentially all anti-CD38 refractory, is quite impressive. If I’m a clinician looking at these data, I’m thinking that the efficacy of this agent is really impressive, not just in terms of complete response rates, which are very good, but in terms of very high rates of MRD negativity. It’s ticking all the boxes for the efficacy aspect of a novel therapy.

Reference

Matous JV, Varga C, Krishnan AY, et al. Updated safety and efficacy of ramantamig (JNJ-5322) at the recommended phase 2 dose demonstrating feasibility of outpatient dosing in relapsed/refractory multiple myeloma. Presented at: 23rd International Myeloma Society Annual Meeting; September 23-26, 2026; Glasgow, Scotland. Abstract OA-70.